Previous close | 8.16 |
Open | 8.15 |
Bid | 7.98 x 0 |
Ask | 8.41 x 0 |
Day's range | 8.11 - 8.24 |
52-week range | 7.20 - 10.08 |
Volume | |
Avg. volume | 47,079 |
Market cap | 1.856B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.06 |
Earnings date | N/A |
Forward dividend & yield | 0.18 (2.03%) |
Ex-dividend date | 12 May 2023 |
1y target est | N/A |
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and W
BARCELONA, Spain, February 19, 2024--Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
BARCELONA, February 19, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.